(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/crwe_tech.jpg

Your Technology Source, Your Technology Team

Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more

Contact Us: contact@crwetech.com

www.CRWETech.com

ad2

http://crweworld.com/assets/images/ad/ad4.png

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com

ad5

http://crweworld.com/assets/images/ad/Pathology_Laboratories.png

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.

www.QuestDiagnostics.com






1329 Result: medical

Pluristem Reports Second Quarter Fiscal 2017 Highlights & Provides Calendar 2017 Outlook

February 13th, 2017

HAIFA, Israel / CRWE PRESS RELEASE / February 13, 2017 - Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PSTI), a leading developer of placenta-based cell therapy products, today reported financial update and corporate and clinical developments for . Read more

Kitov Provides Further Update on Formal Investigation by Israeli Securities Authority

February 09th, 2017

Tel Aviv, Israel / CRWE PRESS RELEASE / February 9, 2017 - Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV; TASE: KTOV), an innovative biopharmaceutical company, in response to requests made by the NASDAQ Stock Market, today provided a further upda. Read more

EyeGate Pharma Announces Positive Top-line Data from First-in-Human Pilot Trial of Ocular Bandage Gel in Corneal Epithelial Defects

January 30th, 2017

Company Plans to Continue Development with Next Controlled Trial Q2 2017 WALTHAM, Mass. / CRWE PRESS RELEASE / January 30, 2017 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharma. Read more

Inovalon Announces Agreement with Boehringer Ingelheim to Support Outcome-Based Contracting

January 23rd, 2017

Inovalon platform to empower expanded insight and improvement in outcomes for value-based medication offerings Bowie, Md. / CRWE PRESS RELEASE / January 23, 2017 – Inovalon (Nasdaq: INOV), a leading technology company providing advanced, clo. Read more

Pluristem Receives Clearance from Germany to Initiate its Multinational Phase III Trial in Critical Limb Ischemia Targeting Early Conditional Marketing Approval

January 17th, 2017

* PLX-PAD cells could potentially obtain early conditional marketing approval in Europe via the Adaptive Pathways pilot project based on positive interim efficacy data from first 125 patients * This approval joins those from the U.S. FDA and U.K. fo. Read more

Transgenomic Announces Leading Clinical Laboratory Services Provider LifeLabs Selects ICE COLD-PCR as its Mutation Enrichment Platform

January 12th, 2017

Three-Year Renewable Agreement Also Includes Non-Exclusive License to ICP in Canada New Patent Has Issued Covering ICE COLD-PCR Technology in Canada OMAHA, Neb. / CRWE PRESS RELEASE / January 12, 2017 - Transgenomic, Inc. (TBIO) (NASDAQ: . Read more

NOVADAQ Announces Preliminary Unaudited Fourth Quarter 2016 Revenue and Issues 2017 Revenue Guidance

January 11th, 2017

Secures up to $60 million in financing from Midcap Financial Toronto, Ontario / CRWE PRESS RELEASE / January 10, 2017 - NOVADAQ Technologies Inc (NASDAQ:NVDQ; TSX:NDQ), the leading provider of proven comprehensive fluorescence . Read more

Puma Biotechnology Expands Cohort in Phase II SUMMIT Trial of PB272 in HER2 Mutation-Positive Cancer Patients

January 06th, 2017

LOS ANGELES, Calif. / CRWE PRESS RELEASE / Jan. 6, 2017 - Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, has expanded the fourth cohort from its Phase II SUMMIT clinical trial of its lead drug candidate PB272 (neratinib) as a s. Read more

BlackBerry QNX Launches its Most Advanced and Secure Embedded Software Platform for Autonomous Drive and Connected Cars

January 04th, 2017

LAS VEGAS, NEVADA / CRWE PRESS RELEASE / Jan. 4, 2017 - International CES 2017, LVCC North Hall, Booth 7029 - BlackBerry Limited (NASDAQ:BBRY) (TSX:BB) today announced its most advanced and secure embedded operating system (OS) for the automotive ind. Read more

Pluristem and New York Blood Center to Collaborate in Evaluating PLX-R18 as an Adjuvant Therapy to Umbilical Cord Blood Transplantation, Winning $900,000 Funding From BIRD

December 27th, 2016

* Prior research has suggested that PLX-R18 helps cord blood cells to engraft more rapidly and effectively * Grant of $900,000 from Israel-U.S. Binational Industrial Research and Development Foundation (BIRD) to fund the research * Constitutes a 3r. Read more

vTv Therapeutics Announces Positive Topline Results from Phase 2 Study of TTP273 in Type 2 Diabetes

December 14th, 2016

Oral small molecule GLP-1 receptor agonist met primary endpoint Company’s second successful Phase 2 diabetes trial in 2016 High Point, North Carolina / CRWE PRESS RELEASE / December 14, 2016 - vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) to. Read more

Puma Biotechnology Presents Results of Biomarker Analysis of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer at the 2016 San Antonio Breast Cancer Symposium

December 07th, 2016

LOS ANGELES, Calif. / CRWE PRESS RELEASE / December 7, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that a biomarker analysis of the NSABP FB-7 Phase II clinical trial of Puma's investigational drug PB. Read more

Pluristem's PLX-R18 Advances into Second Cohort of Dose Selection Study for Treatment of Acute Radiation Syndrome

December 06th, 2016

* NIH’s NIAID completes first cohort of dose selection study * Data from completed study expected in first half of 2017 * Upon determining the optimal dose, a pivotal trial could be conducted to support marketing authorization of PLX-R18 for . Read more

Topline results of Phase 3 investigational study of VONVENDI(TM) [von Willebrand factor (Recombinant)] meets primary endpoint effectively controlling bleeding and blood loss during surgical procedures

December 02nd, 2016

Results will form the basis of a supplemental new drug application to the U.S. Food & Drug Administration, requesting an expanded indication for VONVENDI Lexington, Mass. – December 2, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG), the lea. Read more

Aurinia Highlights Speed of Remission from Global Phase IIb AURA Study of Voclosporin in LN

November 16th, 2016

Late breaking abstract showcases first global study of active lupus nephritis to meet its primary endpoint, presented on November 15th Victoria, British Columbia / CRWE PRESS RELEASE / November 16, 2016 - Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH). Read more

Load More Content